Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Industry–academia collaborations for biomarkers

Abstract

Several types of collaboration are being pursued to identify, validate and apply new biomarkers. Here, we highlight examples of such initiatives and discuss the challenges, approaches to address these challenges and key factors for success.

Your institute does not have access to this article

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Wholley, D. The Biomarkers Consortium. Nat. Rev. Drug. Discov. 13, 791–792 (2014).

    CAS  Article  PubMed  Google Scholar 

  2. Stephenson, D. & Sauer, J. M. The Predictive Safety Testing Consortium and the Coalition Against Major Diseases. Nat. Rev. Drug. Discov. 13, 793–794 (2014).

    CAS  Article  PubMed  Google Scholar 

  3. Lessl, M. et al. Crowd sourcing in drug discovery. Nat. Rev. Drug. Discov. 10, 241–242 (2011).

    CAS  Article  PubMed  Google Scholar 

  4. Küffner, R. et al. Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nat. Biotech. 33, 51–57 (2015).

    Article  Google Scholar 

  5. Dorsch, H. et al. Grants4Targets — an open innovation initiative to foster drug discovery collaborations between academia and the pharmaceutical industry. Nat. Rev. Drug. Discov. 14, 74–76 (2015).

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank T. Schlange, M. Lessl, H. Dorsch (all at Bayer, Germany), and H.-D. Volk (at the Berlin-Brandenburg Center for Regenerative Therapies, Charité, Berlin, Germany) for helpful discussions, and P. Carrigan for critical reading of the manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Khusru Asadullah.

Ethics declarations

Competing interests

L.L. and P.R. have no conflict of interest to declare. K.A., A.B. and M.G. are employees and shareholders of Bayer.

Supplementary information

Supplementary information S1 (table)

Examples of biomarker consortia supported by public funding in Europe and the United States (PDF 92 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Asadullah, K., Busch, A., Gottwald, M. et al. Industry–academia collaborations for biomarkers. Nat Rev Drug Discov 14, 805–806 (2015). https://doi.org/10.1038/nrd4727

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4727

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing